This website is optimized for visualization with Firefox and Internet Explorer (8 or 9)

CLINICAL DEVELOPMENT PIPELINE

Regulatory Review

Phase III

Phase II

  • IL-23 antibody
    LY3074828 (IL-23 antibody) is a biologic entity that blocks the activity of the cytokine interleukin 23. LY3074828 is being studied for the treatment of ulcerative colitis.

    For more information on LY3074828 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • BMP-6 MAb anemia
    LY3113593 (BMP-6 antibody) is a fully humanized antibody that binds to the bone morphogenetic protein-6 and inhibits its activity. LY3113593 is being studied for the treatment of anemia. For more information on LY3113593 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • PCSK9 Monoclonal Antibody
    LY3015014 (PCSK9 monoclonal antibody) is a biologic entity that binds to and inhibits the activity of proprotein convertase subtilisin/kexin type 9. LY3015014 is being studied for the treatment of cardiovascular disease.

    For more information on LY3015014 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.


     
  • Ultra Rapid Insulin
    URI is pursued pre-FRD through two approaches, BioChaperone insulin lispro in collaboration with Adocia and an internal ultra-rapid formulation project of insulin lispro. Both projects are biologic entities being studied for the treatment of type 1 and type 2 diabetes.

    For more information on BioChaperone Lispro clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Myostatin Monoclonal Antibody
    LY2495655 (myostatin monoclonal antibody), a biologic entity, is a fully humanized antibody that inhibits myostatin activity. LY2495655 is being studied for the treatment of disuse muscle atrophy.

    For more information on LY2495655 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Edivoxetine (e" di vox' e teen hye" droe klor' ide)
    LY2216684 (edivoxetine) is a chemical entity that inhibits the reuptake of norepinephrine. LY2216684 is being studied for multiple CNS disorders. Molecule is owned by a 3rd party, Lilly retains rights.

    For more information on edivoxetine clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Prexasertib (prex” a ser’ tib)
    LY2606368 monomesylate monohydrate (formerly known as Chk1 inhibitor) is a chemical entity that preferentially binds to and inhibits checkpoint kinase 1 (Chk1), a global regulator of the mammalian cell cycle and, to a lesser extent, inhibits Chk2. LY2606368 monomesylate monohydrate is being studied for the treatment of cancer.

    For more information on LY2606368 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • CXCR4 Peptide Antagonist
    LY2510924 (CXCR4 peptide antagonist) is a biologic entity that antagonizes ligand binding to the CXC chemokine receptor 4. LY2510924 is being studied for the treatment of cancer.

    For more information on LY2510924 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Emibetuzumab (em” i be tooz’ ue mab)
    LY2875358 (formerly known as c-Met antibody), a biologic entity, was designed as a bivalent c-Met antibody that has neutralization and internalization activity with minimal agonistic activity. LY2875358 is being studied for the treatment of NSCLC.

    For more information on LY2875358 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • FGF Receptor Inhibitor
    LY2874455 (FGF receptor inhibitor), a chemical entity, inhibits autophosphorylation of fibroblast growth factor (FGF) receptors 1, 2, 3 and 4, which is required for activation of FGF-induced downstream signaling. LY2874455 is being studied for the treatment of cancer.

    For more information on LY2874455 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Galunisertib (gal ue” ni ser’ tib)
    LY2157299 monohydrate (formerly known as TGFb R1 kinase inhibitor) is a chemical entity that selectively blocks transforming growth factor-β receptor I kinase and TGF-b signaling. LY2157299 monohydrate is being studied for the treatment of pancreatic and hepatocellular cancer.

    For more information on LY2157299 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Merestinib cancer (mer es’ ti nib)
    LY2801653 (formerly known as c-Met inhibitor) is a chemical entity that has been shown in vitro to be a reversible type II ATP-competitive inhibitor of MET, a receptor for hepatocyte growth factor. Preclinical testing also has shown LY2801653 to inhibit several other receptor tyrosine oncokinases including MST1R, FLT3, AXL, MERTK, TEK, ROS1, and DDR1/2 and the serine/threonine kinases MKNK1/2. LY2801653 is being studied for the treatment of cancer.

    For more information on LY2801653 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • NOTCH inhibitor cancer
    LY3039478 (NOTCH Inhibitor) is a new chemical entity being studied for the treatment of cancer.

    For more information on LY3039478 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • PI3 Kinase/mTOR Dual Inhibitor
    LY3023414 (PI3 Kinase/mTOR dual Inhibitor) is a chemical entity being studied for the treatment of prostate cancer and NSCLC.

    For more information on LY3023414 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Ralimetinib (ral’’ i me’ ti nib)
    LY2228820 dimesylate (formerly known as p38 MAP kinase inhibitor) is a chemical entity that preferentially binds to and inhibits p38 MAP kinase. LY2228820 dimesylate is being studied for the treatment of ovarian cancer.

    For more information on LY2228820 dimesylate clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Baricitinib
    atopic dermatitis
    LY3009104 (baricitinib, formerly known as JAK1/JAK2 Inhibitor) is a chemical entity that inhibits the activity of the Janus (JAK) 1 and 2 enzymes. LY3009104 is being studied for the treatment of atopic dermatitis.

    For more information on LY3009104 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Baricitinib
    systemic lupus erythematosus
    LY3009104 (baricitinib, formerly known as JAK1/JAK2 Inhibitor) is a chemical entity that inhibits the activity of the Janus (JAK) 1 and 2 enzymes. LY3009104 is being studied for the treatment of systemic lupus erythematosus.

    For more information on LY3009104 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Baricitinib
    psoriasis
    LY3009104 (baricitinib, formerly known as JAK1/JAK2 Inhibitor) is a chemical entity that inhibits the activity of the Janus (JAK) 1 and 2 enzymes. LY3009104 is being studied for the treatment of psoriasis.

    For more information on LY3009104 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Abemaciclib (a be muh sī klib)
    LY2835219 (abemaciclib), a chemical entity, is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 that inhibits phosphorylation of the Rb tumor suppressor protein and thereby induces G1 cell cycle arrest. LY2835219 is being studied for the treatment of squamous NSCLC.

    For more information on LY2835219 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Baricitinib
    diabetic nephropathy
    LY3009104 (baricitinib, formerly known as JAK1/JAK2 Inhibitor) is a chemical entity that inhibits the activity of the Janus (JAK) 1 and 2 enzymes. LY3009104 is being studied for the treatment of diabetic nephropathy.

    For more information on LY3009104 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Florbenazine (flor ben' a zeen)
    Florbenazine (18F-AV-133) is a chemical entity PET imaging agent being studied for the imaging of Parkinson's disease pathology.

    For more information on 18F-AV-133 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Phase I

  • diabetes
    New chemical entity. Molecule is owned by a 3rd party, Lilly retains rights.

     
  • DGAT-2 inhibitor dyslipidemia
    "DGAT-2 inhibitor" is a new chemical entity being studied for the treatment of dyslipidemia.

     
  • GIP/GLP-1 Co-agonist Peptide
    "GIP/GLP-1 Co-agonist Peptide" is a new biologic entity being studied for the treatment of diabetes.

     
  • hypoglycemia
    New biologic entity.

     
  • Blosozumab (bloe soz' ue mab)
    LY2541546 (blosozumab) is a new biologic entity that binds and neutralizes sclerostin. LY2541546 is being studied as a treatment for osteoporosis.

     
  • BAFF/IL-17 Bispecific Antibody
    "BAFF/IL-17 Bispecific Antibody" is a new biologic entity being studied for the treatment of immune diseases.

     
  • BTK inhibitor
    "BTK inhibitor" is a new chemical entity being studied for the treatment of immune diseases.

     
  • CXCR1/2 Ligands Antibody
    "CXCR1/2 Ligands Antibody" is a new biologic entity being studied for the treatment of immune diseases.

     
  • IL-21 Antibody
    "IL-21 Antibody" is a new biologic entity being studied for the treatment of immune diseases.

     
  • A ß antibody Fab PEG Alzheimer's
    "A b Antibody Fab PEG" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  • BACE inhibitor Alzheimer's
    "BACE Inhibitor" is a new chemical entity being studied for the treatment of Alzheimer's disease.

     
  • D1 potentiator
    "D1 potentiator" is a new chemical entity being studied for the treatment of dementia.

     
  • N3pG-Aß Monoclonal Antibody
    "N3pG-Aß Monoclonal Antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  • Tau Antibody
    "Tau Antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  • Pomaglumetad methionil
    LY2140023 monohydrate (pomaglumetad methionil) is a chemical entity agonist of the metabotropic glutamate 2/3 receptors. LY2140023 licensed to Denovo Biopharma to identify genetic biomarkers and to screen for appropriate patient subsets for further study in future clinical trials.

     
  • Angiopoietin 2 MAb cancer
    "Angiopoietin 2 Antibody" is a new biologic entity being studied for the treatment of cancer.

     
  • Chk1 Inhibitor
    "Chk1 Inhibitor" is a new chemical entity being studied for the treatment of cancer. Molecule is owned by a 3rd party, Lilly retains rights.

     
  • CSF-1R Monoclonal Antibody
    "CSF-1R Monoclonal Antibody" is a new biologic entity being studied for the treatment of cancer.

     
  • FGFR3-ADC cancer
    "FGFR3-ADC" is a new biologic entity being studied for the treatment of cancer.

     
  • Met/EGFR Bispecific Antibody
    "Met/EGFR Bispecific Antibody" is a new biologic entity being studied for the treatment of cancer.

     
  • Pan-Raf inhibitor
    "Pan-Raf inhibitor" is a new chemical entity being studied for the treatment of cancer.

     
  • PD-L1 Antibody
    "PD-L1 Antibody" is a new biologic entity being studied for the treatment of cancer.

     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Pipeline Disclaimer
The information included on this site reflects Eli Lilly and Company's clinical development pipeline and is not intended for promotional purposes. It includes both new molecular entities as well as select new indications or line extensions of currently-approved products, that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued, delayed or fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of July 19, 2016. Lilly assumes no duty to update this information.

For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being studied is listed.
  • NME
  • Select NILEX
  • Diagnostic